ImmunoACT
PrivateLast Round
Series B
May 31, 2023
Est. Valuation
$133.61M
Total Funding Raised
$19.99M
Company Overview
ImmunoACT is a biotechnology company that develops and commercializes affordable CAR-T cell therapies for the treatment of various blood cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ImmunoACT Comparables
Compare ImmunoACT with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Immuneel Therapeutics | 92% | |
| Cellogen Therapeutics | 82% | |
| JW Therapeutics | 77% |
ImmunoACT Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 31, 2023 | ||||
| Series A | Nov 19, 2021 | ||||
| Grant | Mar 8, 2019 |
Key People
Founding team and executive leadership
ImmunoACT Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Biotechnology Industry Research Assistance Council | Grant |
| Tata Trusts | Grant |
| Society for Innovation and Entrepreneurship | Accelerator, Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 1, 2025
Presented NexCAR19 CAR-T therapy at ESTIC 2025.
- Feb 1, 2025
Launched NexCAR19, India's first indigenous CAR-T therapy.
ImmunoACT Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about ImmunoACT's valuation, stock price, and market status.
Is ImmunoACT a public or private company?
ImmunoACT is a private company.
What is the current stock price of ImmunoACT?
ImmunoACT is a private company with no public stock price. No recent secondary market data is available.
How much is ImmunoACT worth (valuation)?
ImmunoACT's valuation is estimated at $133.6M based on funding round data.
Can I buy ImmunoACT stock?
ImmunoACT shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was ImmunoACT's last funding round?
ImmunoACT's most recent funding round was Series B on May 31, 2023.
Who are the main investors in ImmunoACT?
Key investors in ImmunoACT include Society for Innovation and Entrepreneurship.
Will ImmunoACT IPO soon?
No public IPO plans have been announced for ImmunoACT.
How can I track ImmunoACT secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ImmunoACT's secondary market activity and sign up for updates.